TY - JOUR T1 - Does Biological Therapy Protect against Severe COVID-19? JF - medRxiv DO - 10.1101/2020.06.21.20136788 SP - 2020.06.21.20136788 AU - Ramon Mazzucchelli AU - Raquel Almodovar González AU - Natalia Crespi Villarías AU - Elena García Zamora AU - Elia Pérez Fernández AU - Javier Quirós Donate AU - Monserrat Pérez Encinas AU - Patricia Sanmartín Fenollera AU - María Velasco AU - Pilar López Serrano AU - Jose Lázaro Perez Calle AU - Conrado Fernández Rodríguez AU - José Luis López-Estebaranz AU - Pedro Zarco Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/24/2020.06.21.20136788.abstract N2 - Objective To estimate COVID-19 infection incidence rate with severe affectation (requiring hospitalization) in patients with biological treatment due to rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA), psoriasis (Ps), and inflammatory bowel disease (IBD) and compare it with incidence rate in the general population.Methods Retrospective observational study based on information provided by two administrative databases. One of these two databases contains information on all patients seen in our hospital and diagnosed with COVID-19 infection between March 4th 2020 and April 26th 2020. The other database contains data from patients seen at Rheumatology, Dermatology and Digestive Departments in our hospital who are currently receiving biological therapy. We calculated the crude and age and sex adjusted incidence in both groups. To compare both groups we calculated the Incidence Rate Ratio.Results There was a total of 2,182 patients with COVID-19 requiring hospitalization. Four patients out of a total of 797 patients receiving biological therapy had contracted COVID-19 and required hospital care. Crude incidence rate of COVID-19 requiring hospital care among the general population was 1.41%, and it was 0.50% among the group receiving biological therapy. Rates adjusted by age and sex in the biological group was 0.45% (CI95% 0.11-4.13). The IRR of the group receiving biological therapy compared to the general population was 0.39 (CI95% 0.14-1, p=0.049).Conclusion Findings suggest that prior use of biological therapy does not associate with severe manifestations of COVID-19, and it is likely to have a protective effect against them when compared to the general population.What is already known about this subject?Covid-19 susceptibility in patients with immune-mediated disorders and receiving treatment with biological therapy is unknown.What does this study add?Severe manifestation incidence rate in patients with immune-mediated disorders receiving biological therapy treatment is not increased when compared to the general population.Biological therapies might protect patients from presenting severe COVID-19 manifestations.How might this impact on clinical practice?These data could be used for current recommendations regarding management of patients receiving biological therapies.Mini Abstract The objective of this study is to analyze the incidence rate of severe COVID-19 requiring hospital care for patients receiving biological therapy and to compare it to the general population. Patients treated with biological therapy have crude and adjusted incidence rates under those of the general population.Statement of Human and Animal Rights This article does not contain any studies involving human participants or animals that were performed by the authors. For this type of study, formal consent was therefore not required.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was authorized by the Ethics Committee for Clinical Research of the Hospital Universitario Fundacion Alcorcon.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of the database will be on request to the email: rmazzucchelli{at}fhalcorcon.es ER -